<DOC>
	<DOCNO>NCT01171859</DOCNO>
	<brief_summary>This study conduct explore potential benefit twelve-month doxycycline ( best tolerate dose 200 mg/day ) tauroursodeoxycholic acid ( 750 mg/day ) treatment disease progression patient affect transthyretin amyloidosis , include : 1 ) patient eligible liver transplantation ; 2 ) patient eligible liver transplantation , `` bridge '' therapy time diagnosis surgery , aim stabilize disease ; 3 ) patient show disease progression liver transplantation perform since least 1 year . It phase II , therapeutic exploratory , two-part , 18-month , single centre , prospective study . Part I 12-month , open label treatment period doxycycline ( 200 mg/day , continuously ) tauroursodeoxycholic acid ( 750 mg/day continuously ) administer 40 consent subject transthyretin amyloidosis . Part II withdrawal period subject monitor disease progression . During part I , subject evaluate baseline ( study Day 0 ) , 3 , 6 , 9 12 month doxycycline plus tauroursodeoxycholic acid treatment premature treatment discontinuation ; part II , assess month 15 18 . Monthly phone contact blood test perform monitor potential adverse event .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Doxycycline Plus Tauroursodeoxycholic Acid Transthyretin Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Histochemical diagnosis amyloidosis base detection polarize microscopy green birefringent material Congo redstained tissue specimen ; Molecular definition transthyretin ( TTR ) mutation immunohistochemical staining amyloid fibrils antiTTR antibody ; ECOG performance status ( PS ) 0 , 1 , 2 ; New York Heart Association ( NYHA ) class ≤III Systolic blood pressure ≥100 mmHg ( stand ) Must symptomatic organ involvement amyloid justify therapy ; must evidence neuropathy and/or cardiomyopathy progression liver transplantation perform since least one year . Contraception woman childbearing potential . Medically approved contraception could include abstinence . A negative serum pregnancy test require prior initiation treatment study medication . Liver transplantation previous 12 month liver transplantation anticipate less 6 month ; ALT and/or AST ≥ 2 x Upper Normal Limit ( UNL ) ; Alkaline phosphatase ≥ 2 x UNL ; Creatinine clearance &lt; 30 ml/min ; Any lab value opinion investigator might place subject unacceptable risk participation study ; Echocardiographic ejection fraction &lt; 50 % ; Other neuropathy , due vitamin B12 deficiency , alcoholism , hypothyroidism , uremia , diabetes mellitus , vasculitides ; History poor compliance ; History hypersensitivity ingredient study therapy ; Use investigational drug , device ( biologic ) within 4 week prior study entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>transthyretin</keyword>
	<keyword>doxycycline</keyword>
	<keyword>Tauroursodeoxycholic acid</keyword>
</DOC>